TECH - Bio-Techne - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US09073M1045

Proteins, Antibodies, Reagents, Instruments, Diagnostics, Assays, Genomics

Bio-Techne Corporation is a leading life science company that develops, manufactures, and sells a wide range of products and services for the research and clinical diagnostic markets globally. With a strong presence in the United States, the United Kingdom, Europe, Middle East, Africa, Greater China, and Asia-Pacific, the company operates through two main segments: Protein Sciences and Diagnostics and Genomics.

The Protein Sciences segment is a key player in the development and manufacturing of biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy. This includes cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. Additionally, the segment offers proteomic analytical tools, such as automated western blot and multiplexed ELISA workflow, which consist of manual and automated protein analysis instruments and immunoassays for quantifying proteins in various biological fluids.

The Diagnostics and Genomics segment focuses on developing and manufacturing diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market. This segment also offers exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications. Furthermore, the segment sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications.

Bio-Techne Corporation has a rich history, dating back to 1976, and was formerly known as Techne Corporation before changing its name in November 2014. The company is headquartered in Minneapolis, Minnesota, and is committed to advancing life science research and diagnostics through its innovative products and services. For more information, visit their website at https://www.bio-techne.com.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for TECH - Bio-Techne  - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for TECH - Bio-Techne  - Stock Price & Dividends

TECH Stock Overview

Market Cap in USD 11,258m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Life Sciences Tools & Services
TER 0.00%
IPO / Inception 1989-02-09

TECH Stock Ratings

Growth 5y 21.6
Fundamental 65.4
Dividend 27.3
Rel. Performance vs Sector 0.33
Analysts 4.27/5
Fair Price Momentum 73.53 USD
Fair Price DCF 42.02 USD

TECH Dividends

Dividend Yield 12m 0.40%
Yield on Cost 5y 0.61%
Dividends CAGR 5y 0.00%
Payout Consistency 96.0%

TECH Growth Ratios

Growth 12m -3.37%
Growth Correlation 12m 10%
Growth Correlation 3m -20%
CAGR 5y 8.96%
CAGR/Mean DD 5y 0.39
Sharpe Ratio 12m -0.25
Alpha vs SP500 12m -24.39
Beta vs SP500 5y weekly 1.01
ValueRay RSI 85.02
Volatility GJR Garch 1y 33.28%
Price / SMA 50 4.96%
Price / SMA 200 13.84%
Current Volume 969.1k
Average Volume 20d 1044.2k

External Links for TECH Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
XStocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of TECH stocks?
As of July 27, 2024, the stock is trading at USD 80.60 with a total of 969,063 shares traded.
Over the past week, the price has changed by +6.81%, over one month by +11.79%, over three months by +25.95% and over the past year by -2.92%.
What are the forecast for TECH stock price target?
According to ValueRays Forecast Model, TECH Bio-Techne will be worth about 81.7 in July 2025. The stock is currently trading at 80.60. This means that the stock has a potential upside of +1.34%.
Issuer Forecast Upside
Wallstreet Target Price 83.8 3.93
Analysts Target Price 101 25.3
ValueRay Target Price 81.7 1.34